Bluejay Diagnostics Inc's fundamentals are relatively very healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 244/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Bluejay Diagnostics Inc's Score
Industry at a Glance
Industry Ranking
244 / 404
Overall Ranking
518 / 4562
Industry
Biotechnology & Medical Research
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
0
analysts
--
Current Rating
0.000
Target Price
0.00%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Bluejay Diagnostics Inc Highlights
StrengthsRisks
Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes in critical care settings. It develops rapid tests using whole blood on its Symphony technology platform (Symphony), which consists of an analyzer and single-use protein detection cartridges that have the function of automatic stepwise feeding of reagent. The Symphony device is designed to produce laboratory-quality results in 20 minutes in critical care settings, including Intensive Care Units (ICUs) and Emergency Rooms (ERs). Its product candidate, the Symphony IL-6 test, is an immunoassay for the measurement of interleukin-6 (IL-6) to be used for the monitoring of disease progression in critical care settings. It is focused on pursuing the Symphony IL-6 test in the context of sepsis. IL-6 is a clinically established inflammatory biomarker, and is considered a 'first-responder', for the assessment of severity of infection and inflammation across many disease indications, including sepsis.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Fairly Valued
The company’s latest PE is -0.01, at a medium 3-year percentile range.
Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes in critical care settings. It develops rapid tests using whole blood on its Symphony technology platform (Symphony), which consists of an analyzer and single-use protein detection cartridges that have the function of automatic stepwise feeding of reagent. The Symphony device is designed to produce laboratory-quality results in 20 minutes in critical care settings, including Intensive Care Units (ICUs) and Emergency Rooms (ERs). Its product candidate, the Symphony IL-6 test, is an immunoassay for the measurement of interleukin-6 (IL-6) to be used for the monitoring of disease progression in critical care settings. It is focused on pursuing the Symphony IL-6 test in the context of sepsis. IL-6 is a clinically established inflammatory biomarker, and is considered a 'first-responder', for the assessment of severity of infection and inflammation across many disease indications, including sepsis.
Ticker SymbolBJDX
CompanyBluejay Diagnostics Inc
CEODey (Neil)
Websitehttps://bluejaydx.com/
FAQs
What is the current price of Bluejay Diagnostics Inc (BJDX)?
The current price of Bluejay Diagnostics Inc (BJDX) is 0.706.
What is the symbol of Bluejay Diagnostics Inc?
The ticker symbol of Bluejay Diagnostics Inc is BJDX.
What is the 52-week high of Bluejay Diagnostics Inc?
The 52-week high of Bluejay Diagnostics Inc is 10.200.
What is the 52-week low of Bluejay Diagnostics Inc?
The 52-week low of Bluejay Diagnostics Inc is 0.712.
What is the market capitalization of Bluejay Diagnostics Inc?
The market capitalization of Bluejay Diagnostics Inc is 1.16M.
What is the net income of Bluejay Diagnostics Inc?
The net income of Bluejay Diagnostics Inc is -34.16M.
Is Bluejay Diagnostics Inc (BJDX) currently rated as Buy, Hold, or Sell?
According to analysts, Bluejay Diagnostics Inc (BJDX) has an overall rating of --, with a price target of --.
What is the Earnings Per Share (EPS TTM) of Bluejay Diagnostics Inc (BJDX)?
The Earnings Per Share (EPS TTM) of Bluejay Diagnostics Inc (BJDX) is -99.673.